À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀº 2023³â 134¾ï 3,117¸¸ ´Þ·¯·Î Æò°¡µÇ°í 2031³â¿¡´Â 216¾ï 7,000¸¸ ´Þ·¯¿¡ ´ÞÇÒ °ÍÀ¸·Î ¿¹»óµÇ¸ç, 2023³âºÎÅÍ 2031³â±îÁö ¿¬Æò±Õ 6.2%ÀÇ ¼ºÀå·üÀ» º¸ÀÏ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
ÀÓ»ó½ÃÇè ¼ö Áõ°¡°¡ À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀ» ÁÖµµ
ÀÓ»ó½ÃÇèÀº ½Å¾à, ½ÄÀÌ¿ä¹ý, ÀÇ·á±â¼ú µî »õ·Î¿î Ä¡·á¹ýÀ̳ª ¿¹¹æ¹ýÀÌ ¾ÈÀüÇϰí È¿°úÀûÀÎÁö Æò°¡ÇÏ´Â µ¥ µµ¿òÀÌ µË´Ï´Ù. ÀÓ»ó½ÃÇèÀº ÁÖ·Î ÀǾàǰ °³¹ß ´Ü°è¿¡¼ ½Ç½ÃµË´Ï´Ù. À¯·´ÀǾàǰû¿¡ µû¸£¸é À¯·´¿¬ÇÕ(EU)¿¡¼´Â ¿¬°£ ¾à 4,000°ÇÀÇ ÀÓ»ó½ÃÇèÀÌ ½ÂÀεǰí ÀÖÀ¸¸ç, Á¦¾à ¾÷°è°¡ ¾à 60%¸¦ Â÷ÁöÇϰí ÀÖ½À´Ï´Ù. ¸¸¼ºÁúȯÀÇ Áõ°¡·Î ÀÎÇØ ´Ù¾çÇÑ È¿°úÀûÀÎ Ä¡·á¹ýÀ» °³¹ßÇϱâ À§ÇÑ ÀÓ»ó½ÃÇèÀÇ ¼ö°¡ Áõ°¡Çϰí ÀÖ½À´Ï´Ù. ÀÓ»ó½ÃÇèÀº Á¡Â÷ º¹ÀâÇØÁö°í ÀÖÀ¸¸ç, ¿¬±¸ ±â¹Ý Á¶Á÷¿¡¼ ¼öÇàµÇ´Â ¾÷¹«ÀÇ ÀûÀýÇÑ ½ÇÇà°ú ¸ð´ÏÅ͸µÀÌ Áß¿äÇØÁö°í ÀÖ½À´Ï´Ù. R&D ±â°üµéÀº ºÎÀûÀýÇÑ ¼öÇàÀ¸·Î ÀÎÇÑ ½Ç¼ö¸¦ ÇÇÇϱâ À§ÇØ Á¦Ç° °³¹ß°ú µ¿½Ã¿¡ ÀÓ»ó½ÃÇèÀ» ¾Æ¿ô¼Ò½ÌÇϰí ÀÖ½À´Ï´Ù. ·¹ÆÛ·±½º ·¦Àº °úÇаú ±â¼úÀÇ ¹ßÀü¿¡ ´ëÀÀÇϱâ À§ÇÑ Àû±ØÀûÀÎ Á¢±Ù ¹æ½ÄÀ¸·Î Àß ¾Ë·ÁÁ® ÀÖ½À´Ï´Ù. ·¹ÆÛ·±½º ·¦Àº »õ·Î¿î Áø´Ü ±â±â, Àåºñ ¹× ±â¼úÀ» ½Å¼ÓÇÏ°Ô µµÀÔÇϰí ÅëÇÕÇÏ¿© ÀáÀçÀûÀÎ ¿ëµµ¿Í ÀÌÁ¡À» Æò°¡ÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÓ»ó Ç¥ÁØ ½ÇÇè½ÇÀº Àú·ÅÇϰí È¿À²ÀûÀ¸·Î ¼öÇàµÇ´Â Á¾ÇÕÀûÀÎ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ¹× ºñ±³ °Ë»ç ¸Þ´º¸¦ Á¦°øÇÔÀ¸·Î½á ¿¬±¸ÆÀÀÌ ÇÁ·ÎÁ§Æ®¸¦ ¼º°øÀûÀ¸·Î ¼öÇàÇÒ ¼ö ÀÖµµ·Ï Áö¿øÇÕ´Ï´Ù. ÀÓ»ó Ç¥ÁØ ½ÇÇè½ÇÀº ÇÊ¿äÇÑ »ùÇÃÀ» ¼öÁý ¹× Á¦°øÇϰí, ÇØ´ç ½Ã¼³¿¡¼ ÇÊ¿äÇÑ °Ë»ç¸¦ ¼öÇàÇÕ´Ï´Ù. Vimta Labs Ltd, Regional Pathology Services, Boca Bio´Â »ó¾÷Àû ÀÓ»ó½ÃÇè ¼ºñ½º¸¦ Á¦°øÇϰí ÀÖÀ¸¸ç, ÀÌ ¸ðµç ¼ºñ½º¸¦ ÇÑ ÁöºØ ¾Æ·¡¿¡¼ ÀÌ¿ëÇÒ ¼ö ÀÖ½À´Ï´Ù. ÀÌó·³ ÀÓ»ó½ÃÇèÀÇ Áõ°¡´Â ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ÀǾàǰ ½ÃÀåÀÇ ¼ºÀåÀ» ÁÖµµÇϰí ÀÖ½À´Ï´Ù.
À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀå °³¿ä
µ¶ÀÏ¿¡¼´Â ¾Ï, ½ÉÇ÷°üÁúȯ, ½Å°æ°è Áúȯ, °¨¿°¼º ÁúȯÀÌ ÀÓ»ó½ÃÇè¿¡¼ °¡Àå ¸¹ÀÌ Á¶»çµÇ´Â ÁúȯÀÔ´Ï´Ù. ÀÓ»ó ¿¬±¸´Â µ¶ÀÏÀÇ Àß ±¸ÃàµÈ ±³Åë, Åë½Å, ¿¡³ÊÁö, °ø°ø ¼ºñ½º ÀÎÇÁ¶óÀÇ ÇýÅÃÀ» ¹Þ°í ÀÖ½À´Ï´Ù. ±¹¸³º¸°Ç¿¬±¸¿øÀÌ 2023³â 12¿ù ¹ßÇ¥ÇÑ ³í¹®¿¡ µû¸£¸é, µ¶ÀÏ¿¡´Â 400¸¸ ¸í ÀÌ»óÀÌ Èñ±ÍÁúȯÀ» ¾Î°í ÀÖ½À´Ï´Ù. Èñ±ÍÁúȯÀº º¹ÀâÇÑ ÀÓ»ó ÆÐÅÏÀ» °¡Áö°í ÀÖ½À´Ï´Ù. ÀÌ·¯ÇÑ Áúº´À» Ä¡·áÇϱâ À§Çؼ´Â ½Å¼ÓÇÑ ÀÓ»ó½ÃÇè°ú ºü¸¥ ÀÓ»ó °á°ú°¡ ÇÊ¿äÇÕ´Ï´Ù. 2023³â 1¿ù, Premier Research´Â CENTOGENE¿Í ÆÄÆ®³Ê½ÊÀ» ¸Î°í Èñ±ÍÁúȯ ÀÓ»ó °³¹ßÀÇ ¸®½ºÅ©¸¦ ÁÙÀ̱â À§ÇØ ·¹ÆÛ·±½º ·¦ÀÌ Áß¿äÇÑ ¿ªÇÒÀ» ÇÕ´Ï´Ù. ÇÁ¸®¹Ì¾î ¸®¼Ä¡ÀÇ Èñ±ÍÁúȯ Á¦Ç° °³¹ß¿¡ ´ëÇÑ ±¤¹üÀ§ÇÑ Àü¹® Áö½ÄÀº ¼¾ÅäÁøÀÇ ¹ÙÀÌ¿À µ¥ÀÌÅ͹ðÅ©¿Í ¸ÖƼ¿À¹Í½º ·¹ÆÛ·±½º ·¦¿¡¼ »ý¼ºµÇ´Â °í±Þ Áö½Ä¿¡ ÀÇÇØ µÞ¹ÞħµË´Ï´Ù. ¶ÇÇÑ, ¸¸¼º ¹ÙÀÌ·¯½º¼º ÁúȯÀÇ À¯º´·ü Áõ°¡¿Í ¹ÌÃæÁ· ¼ö¿ä¸¦ ÃæÁ·½Ã۱â À§ÇØ ¹ÙÀÌ·¯½º Ä¡·á ºÐ¾ß¿¡ ´ëÇÑ »õ·Î¿î ºÐÀÚ¸¦ »ý»êÇϰíÀÚ ÇÏ´Â ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó µ¶ÀÏ ³» Ç×°¨¿°Áõ ¾à¹°¿¡ ´ëÇÑ ¼ö¿ä°¡ Å©°Ô Áõ°¡Çϰí ÀÖ½À´Ï´Ù. À§ÀÇ ¿äÀÎÀ¸·Î ÀÎÇØ ÀÌ ³ª¶ó ½ÃÀåÀº Å©°Ô ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
2031³â±îÁö À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀå ¼öÀÍ ¹× ¿¹Ãø(±Ý¾×)
À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀå ¼¼ºÐÈ
À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀº ¼ºñ½º Á¦°ø¾÷ü, ¿ëµµ, ±¹°¡º°·Î ºÐ·ùµË´Ï´Ù.
¼ºñ½º Á¦°ø¾÷ü¸¦ ±âÁØÀ¸·Î À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀº º´¿ø ±â¹Ý, µ¶¸³Çü, Ŭ¸®´Ð ±â¹ÝÀ¸·Î ±¸ºÐµË´Ï´Ù. º´¿ø ±â¹Ý ºÎ¹®ÀÌ 2023³â °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇß½À´Ï´Ù.
¿ëµµº°·Î À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀº ÀÓ»ó°Ë»ç, ÀÓ»ó½ÃÇè, ±âŸ·Î ºÐ·ùµÇ¸ç, 2023³â ÀÓ»ó°Ë»ç ºÎ¹®ÀÌ °¡Àå Å« ½ÃÀå Á¡À¯À²À» Â÷ÁöÇÒ °ÍÀ¸·Î ¿¹»óµË´Ï´Ù.
±¹°¡º°·Î À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀåÀº µ¶ÀÏ, ¿µ±¹, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ, ±âŸ À¯·´À¸·Î ±¸ºÐµÇ¸ç, 2023³â À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀå Á¡À¯À²Àº µ¶ÀÏÀÌ µ¶Â÷ÁöÇß½À´Ï´Ù.
Sonic Healthcare Ltd, UNILABS, Laboratory Corp of America Holdings, Quest Diagnostics Inc, SYNLAB International GmbH, Myraid Genetics Inc µîÀº À¯·´ÀÇ ÀÓ»ó Ç¥ÁØ ½ÇÇè½Ç ½ÃÀå¿¡¼ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷µéÀÔ´Ï´Ù.
The Europe clinical reference laboratory market was valued at US$ 13,431.17 million in 2023 and is expected to reach US$ 21,670.00 million by 2031; it is estimated to register a CAGR of 6.2% from 2023 to 2031.
Increasing Number of Clinical Trials Drives Europe Clinical Reference Laboratory Market
Clinical trials assist in evaluating whether a new treatment or prevention method, such as a new medicine, diet, or medical technology, is safe and effective. The trials are primarily conducted during the drug development phase. According to the European Medicine Agency, in the European Union (EU), ~4,000 clinical trials are approved annually, with the pharmaceutical industry accounting for roughly 60%. Due to the growing prevalence of chronic diseases, the number of clinical trials is increasing to develop various effective treatments. Clinical trials are gradually becoming complex procedures, because proper execution and oversight of the operations occurring in research-based organizations have become crucial. Research-based organizations are outsourcing clinical trials while developing their products to avoid errors due to improper execution. Reference laboratories are well-known for their proactive approach to keeping up with scientific and technological advancements. Reference labs promptly adopt and integrate new diagnostic instruments, equipment, and techniques, allowing them to evaluate their potential applications and benefits. Clinical reference labs help research teams successfully conduct their projects by providing a comprehensive menu of clinical and comparative testing performed inexpensively and efficiently. Clinical reference labs collect and provide the required samples and perform the necessary testing at their facility. That means all the services are available under one roof. Vimta Labs Ltd, Regional Pathology Services, and Boca Bio provide commercial clinical trial services. Thus, the increasing number of clinical trials is driving the clinical reference laboratory market growth.
Europe Clinical Reference Laboratory Market Overview
Cancer, cardiovascular illness, nervous system disorders, and infectious diseases are the most frequently studied conditions in clinical trials in Germany. Clinical research benefits from Germany's well-established transport, communication, energy, and public services infrastructure. According to an article published by the National Institutes of Health in December 2023, ~4 million people had a rare disease in Germany. Rare diseases have complex clinical patterns. Treatments for such diseases need accelerated trials and fast-track clinical outcomes. This is where reference laboratories play a crucial role. In January 2023, Premier Research partnered with CENTOGENE to de-risk rare disease clinical development. Premier Research's extensive expertise in rare disease product development will be supported by advanced insights generated by the CENTOGENE Biodatabank and multiomic reference laboratories. Moreover, the demand for anti-infective agents in Germany is growing significantly, attributed to the increasing prevalence of chronic viral diseases and the growing demand to produce new molecules for viral therapeutic areas to fulfill unmet conditions. The market is expected to grow significantly in the country due to the abovementioned factors.
Europe Clinical Reference Laboratory Market Revenue and Forecast to 2031 (US$ Million)
Europe Clinical Reference Laboratory Market Segmentation
The Europe clinical reference laboratory market is categorized into service provider, application, and country.
Based on service provider, the Europe clinical reference laboratory market is segmented into hospital-based, standalone, and clinic-based. The hospital-based segment held the largest market share in 2023.
In terms of application, the Europe clinical reference laboratory market is categorized into laboratory medicine, clinical trials, and others. The laboratory medicine segment held the largest market share in 2023.
By country, the Europe clinical reference laboratory market is segmented into Germany, the UK, France, Italy, Spain, and the Rest of Europe. Germany dominated the Europe clinical reference laboratory market share in 2023.
Sonic Healthcare Ltd, UNILABS, Laboratory Corp of America Holdings, Quest Diagnostics Inc, SYNLAB International GmbH, and Myraid Genetics Inc are some of the leading companies operating in the Europe clinical reference laboratory market.